Comparison of beclomethasone/formoterol and fluticasone/salmeterol fixed combinations for weekly asthma control

G. Nicolini, G. Cremonesi, A. Papi, P. Paggiaro, L. M. Fabbri (Parma, Ferrara, Pisa, Modena, Italy)

Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Session: Recent advances in the treatment and pathogenesis of asthma
Session type: Thematic Poster Session
Number: 3633
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Nicolini, G. Cremonesi, A. Papi, P. Paggiaro, L. M. Fabbri (Parma, Ferrara, Pisa, Modena, Italy). Comparison of beclomethasone/formoterol and fluticasone/salmeterol fixed combinations for weekly asthma control. Eur Respir J 2008; 32: Suppl. 52, 3633

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009


The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control
Source: Eur Respir J 2001; 18: Suppl. 33, 263s
Year: 2001

Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain
Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Year: 2008


Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009


Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001



Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON)
Source: Eur Respir J 2003; 22: Suppl. 45, 259s
Year: 2003

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Efficacy of combined budesonide/formoterol delivered via turbuhaler on lung function and asthma control in asthmatic children
Source: Eur Respir J 2003; 22: Suppl. 45, 496s
Year: 2003

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006